Morgan Stanley’s Cumberland Pharmaceuticals CPIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.1K Buy
3,261
+1
+0% +$5 ﹤0.01% 6795
2026
Q1
$10.6K Hold
3,260
﹤0.01% 6923
2025
Q4
$13K Sell
3,260
-345
-10% -$1.02K ﹤0.01% 6823
2025
Q3
$11.2K Sell
3,605
-8,793
-71% -$29.2K ﹤0.01% 6870
2025
Q2
$41.5K Buy
12,398
+9,738
+366% +$46.1K ﹤0.01% 6418
2025
Q1
$11.3K Hold
2,660
﹤0.01% 6766
2024
Q4
$6.3K Hold
2,660
﹤0.01% 6942
2024
Q3
$3.4K Hold
2,660
﹤0.01% 7012
2024
Q2
$4.07K Sell
2,660
-8,614
-76% -$13.5K ﹤0.01% 6905
2024
Q1
$18.9K Sell
11,274
-11,274
-50% -$22.5K ﹤0.01% 6507
2023
Q4
$40.4K Buy
22,548
+11,274
+100% +$20.7K ﹤0.01% 6444
2023
Q3
$21.3K Hold
11,274
﹤0.01% 6461
2023
Q2
$16.6K Hold
11,274
﹤0.01% 6630
2023
Q1
$22K Sell
11,274
-1
-0% -$2 ﹤0.01% 6590
2022
Q4
$25.4K Sell
11,275
-1,619
-13% -$3.76K ﹤0.01% 6578
2022
Q3
$31K Buy
12,894
+10,234
+385% +$24.1K ﹤0.01% 6605
2022
Q2
$6K Sell
2,660
-495
-16% -$1.15K ﹤0.01% 7351
2022
Q1
$9K Buy
3,155
+484
+18% +$1.61K ﹤0.01% 7432
2021
Q4
$12K Sell
2,671
-501
-16% -$1.71K ﹤0.01% 7408
2021
Q3
$8K Buy
3,172
+12
+0.4% +$36 ﹤0.01% 7389
2021
Q2
$9K Sell
3,160
-8,000
-72% -$23.5K ﹤0.01% 7262
2021
Q1
$34K Buy
11,160
+6,335
+131% +$20.6K ﹤0.01% 6520
2020
Q4
$14K Sell
4,825
-3,677
-43% -$11.1K ﹤0.01% 6544
2020
Q3
$27K Sell
8,502
-2,420
-22% -$7.96K ﹤0.01% 5942
2020
Q2
$36K Sell
10,922
-1,246
-10% -$4.53K ﹤0.01% 5794
2020
Q1
$44K Sell
12,168
-3,136
-20% -$14K ﹤0.01% 5511
2019
Q4
$78K Sell
15,304
-683
-4% -$3.61K ﹤0.01% 5729
2019
Q3
$95K Sell
15,987
-1,467
-8% -$8.16K ﹤0.01% 5461
2019
Q2
$111K Sell
17,454
-1,531
-8% -$9.28K ﹤0.01% 5269
2019
Q1
$110K Buy
18,985
+1,506
+9% +$8.73K ﹤0.01% 5349
2018
Q4
$105K Sell
17,479
-2,035
-10% -$12.2K ﹤0.01% 5537
2018
Q3
$111K Buy
19,514
+281
+1% +$1.66K ﹤0.01% 5654
2018
Q2
$118K Sell
19,233
-1,182
-6% -$7.39K ﹤0.01% 5696
2018
Q1
$137K Buy
20,415
+698
+4% +$4.8K ﹤0.01% 5619
2017
Q4
$145K Sell
19,717
-336
-2% -$2.47K ﹤0.01% 5520
2017
Q3
$142K Sell
20,053
-965
-5% -$6.67K ﹤0.01% 5477
2017
Q2
$147K Sell
21,018
-597
-3% -$3.94K ﹤0.01% 5481
2017
Q1
$150K Buy
21,615
+2,844
+15% +$17.2K ﹤0.01% 5447
2016
Q4
$103K Sell
18,771
-12,473
-40% -$65.1K ﹤0.01% 5560
2016
Q3
$157K Sell
31,244
-6,269
-17% -$29.5K ﹤0.01% 5110
2016
Q2
$169K Sell
37,513
-2,901
-7% -$13.3K ﹤0.01% 5017
2016
Q1
$181K Sell
40,414
-10,466
-21% -$49.9K ﹤0.01% 5038
2015
Q4
$268K Sell
50,880
-6,280
-11% -$35.8K ﹤0.01% 4925
2015
Q3
$330K Sell
57,160
-1,255
-2% -$7.82K ﹤0.01% 4835
2015
Q2
$418K Sell
58,415
-7,453
-11% -$51.8K ﹤0.01% 4835
2015
Q1
$438K Buy
65,868
+3,450
+6% +$21.5K ﹤0.01% 4753
2014
Q4
$373K Buy
62,418
+65
+0.1% +$334 ﹤0.01% 4882
2014
Q3
$308K Sell
62,353
-6,690
-10% -$32.4K ﹤0.01% 4889
2014
Q2
$311K Buy
69,043
+2,544
+4% +$11.4K ﹤0.01% 4916
2014
Q1
$299K Sell
66,499
-24,181
-27% -$115K ﹤0.01% 4889
2013
Q4
$463K Sell
90,680
-61,444
-40% -$300K ﹤0.01% 4504
2013
Q3
$689K Sell
152,124
-96,407
-39% -$480K ﹤0.01% 4097
2013
Q2
$1.27M Buy
+248,531
New +$1.24M ﹤0.01% 3512

Other funds holding CPIX

Morgan Stanley's CPIX Position: Q2 2026 in Review

Morgan Stanley increased its Cumberland Pharmaceuticals (CPIX) stake by 0.03% in Q2 2026, buying an estimated $5 and bringing the position to 3,261 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6795.

Morgan Stanley first reported a position in CPIX in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.27M in Q2 2013. 21 funds tracked by Wall St. Rank hold CPIX as of Q2 2026.

  • Morgan Stanley held 3,261 shares of Cumberland Pharmaceuticals worth $21.1K as of Q2 2026.
  • Morgan Stanley bought 1 Cumberland Pharmaceuticals share in Q2 2026, an estimated $5.
  • Cumberland Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6795 holding.
  • Morgan Stanley first reported a position in Cumberland Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Morgan Stanley's Cumberland Pharmaceuticals position peaked at $1.27M in Q2 2013.
  • 21 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.